{
  "docId": "019de073-7b6a-72bb-8d98-812d56d63617",
  "docSlug": "f8b2787992eb3375620f74057447d0c9",
  "documentTitle": "Aravive | Investor Presentation Deck | 39 slides",
  "authorId": "aravive",
  "authorName": "Aravive",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 39,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 15,
  "notes": "Includes footnotes comparing results to historical METEOR and CANTATA studies.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7b6a-72bb-8d98-812d56d63617/24",
  "deckHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617",
  "deckJsonHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617.json",
  "deckAnchorHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "1 Confirmed objective response rate for (60mg) cabozantinib from METEOR and CANTATA studies was 17% and 28%; Median PFS for (60mg) was 7.4 and 9.3 months; 9-month PFS 36% and 50%\n2 No patient had PD at first scan: One patient had PR at first scan and then progressed; the other 2 patients were SD at first scan and then progressed",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8938bcc-3d4c-4bc9-b9c1-6ef90faa734d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.75,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Data cutoff August 8, 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "60ed9f67-372a-4463-887d-642b0fc2d464",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "table",
      "text": "Efficacy metrics table comparing All Patients, 15mg/kg, and 20mg/kg cohorts across response rates, PFS, and duration of response.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e18994ff-1cd2-4bfa-acec-bda207096a29",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "P1b ccRCC: Clinical Activity of Batiraxcept + Cabozantinib",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "983faef4-0a0a-4498-9d20-1ccb6e192caf",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "7d2cfe73-1122-4dde-9478-26cf1f3808f5",
      "evidence": "table/data: Efficacy metrics table comparing All Patients, 15mg/kg, and 20mg/kg cohorts across response rates, PFS, and duration of response.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}